BIS and montelukast provided acceptable asthma control in children aged 2 to 4 years with mild persistent asthma with no significant difference between treatments in the primary end point ; however , several secondary outcomes showed statistically significant differences ( and many had numerical differences ) in favor of BIS over montelukast .